The smaller cap Healthcare index: After another year of outperformance, during which the AIM healthcare sector rose 10% in 2021 vs 5% for the broader AIM market, we are seeing a rotation out of growth into value stocks in 2022 (this also helped the large cap healthcare stocks rise 17% in 2021). Coupled with a rotation out of COVID-19 diagnostics companies, the AIM Healthcare index has fallen 24% in 2022 YTD (vs AIM -14%). The finnLife 50 index has also fallen, by 27%, with all but two companies ....

25 Feb 2022
Rude Health - finnCap Life Sciences quarterly sector note
4basebio PLC (4BB:LON), 1,125 | Allergy Therapeutics plc (AGY:LON), 6.9 | Bioventix Plc (BVXP:LON), 2,850 | TheraCryf PLC (TCF:LON), 0.2 | Cambridge Nutritional Sciences PLC (CNSL:LON), 2.6 | hVIVO plc (HVO:LON), 17.5 | SDI Group plc (SDI:LON), 57.5 | Shield Therapeutics Plc (STX:LON), 2.6 | Tristel Plc (TSTL:LON), 395 | Destiny Pharma Plc (DTTYF:OTC), 0

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Rude Health - finnCap Life Sciences quarterly sector note
4basebio PLC (4BB:LON), 1,125 | Allergy Therapeutics plc (AGY:LON), 6.9 | Bioventix Plc (BVXP:LON), 2,850 | TheraCryf PLC (TCF:LON), 0.2 | Cambridge Nutritional Sciences PLC (CNSL:LON), 2.6 | hVIVO plc (HVO:LON), 17.5 | SDI Group plc (SDI:LON), 57.5 | Shield Therapeutics Plc (STX:LON), 2.6 | Tristel Plc (TSTL:LON), 395 | Destiny Pharma Plc (DTTYF:OTC), 0
- Published:
25 Feb 2022 -
Author:
Mark Brewer -
Pages:
40 -
The smaller cap Healthcare index: After another year of outperformance, during which the AIM healthcare sector rose 10% in 2021 vs 5% for the broader AIM market, we are seeing a rotation out of growth into value stocks in 2022 (this also helped the large cap healthcare stocks rise 17% in 2021). Coupled with a rotation out of COVID-19 diagnostics companies, the AIM Healthcare index has fallen 24% in 2022 YTD (vs AIM -14%). The finnLife 50 index has also fallen, by 27%, with all but two companies ....